| Literature DB >> 25511989 |
Veronica Milos1,2, Tommy Westerlund3, Patrik Midlöv4, Eva Lena Strandberg5.
Abstract
BACKGROUND: Drug therapy in primary care is a challenge for general practitioners (GPs) and the prescribing decision is influenced by several factors. GPs obtain drug information in different ways, from evidence-based sources, their own or others' experiences, or interactions with opinion makers, patients or colleagues. The need for objective drug information sources instead of drug industry-provided information has led to the establishment of local drug and therapeutic committees. They annually produce and implement local treatment guidelines in order to promote rational drug use. This study describes Swedish GPs' attitudes towards locally developed evidence-based treatment guidelines.Entities:
Mesh:
Year: 2014 PMID: 25511989 PMCID: PMC4276045 DOI: 10.1186/s12875-014-0199-0
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Characteristics of the participants
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | A | F | 57 | 54 | 20 | 20 | Public |
| B | F | 54 | 25 | Public | |||
| C | F | 50 | 15 | Public | |||
| D | F | 45 | 16 | Public | |||
| E | F | 58 | 30 |
| |||
| 2 | A | M | 53 | 53 | 10 | 10 | Public |
| B | F | 61 | 33 | Public | |||
| C | F | 64 | 35 | Public | |||
| D | F | 34 | 4 | Public | |||
| E | F | 38 | 3 | Public | |||
| 3 | A | F | 35 | 40 | 7 | 5 | Public |
| B | F | 48 | 5 | Public | |||
| C | M | 41 | 10 | Public | |||
| D | F | 48 | 5 |
| |||
| E | M | 35 | 5 | Public | |||
| F | F | 40 | 8 | Public | |||
| G | M | 33 | 2 | Public |
Example of text condensation and coding
|
|
| ||
|---|---|---|---|
|
| Beliefs about adherence to guidelines | ||
|
| Reported adherence behaviour in everyday practice | ||
|
| High adherence if guidelines similar to own experience | Lower adherence if more frequent changes to guidelines | High adherence when feeling unsure |
|
| In the case of migraine drugs, when I did not have enough experience to say that the more expensive drugs were better, I supported my argument with the guidelines. | It was decided that the insulin kind would change to another, cheaper one, and soon afterwards it would change back again, but I have learned from previous experience and have not changed anything yet. | When I feel unsure I stick to the guidelines. |
|
| “… and an area where I’ve benefited from them … (guidelines) … in agreement with the patient or against the patient’s will … is when they want migraine drugs, triptans, more expensive ones … and when I didn’t have enough experience to say that that the more expensive ones were better, I supported my argument with the guidelines then …” | “… we were supposed to change from the usual insulin that we had used many years to a cheaper one, and it is a lot of work if you are going to change it for all patients, and then after a couple of months they lowered the price of the first one, so there was no difference any more. But I have some previous experience and have not changed anything yet, but will wait and see what happens.” | “You feel sometimes that you should be more informed, but if I feel unsure I stick to the guidelines”. |
Categories and themes
|
|
|
|---|---|
| Expectations and perceptions about existing local guidelines |
|
| Knowledge about evidence-based prescribing | |
| Trust in development of guidelines | |
| Beliefs about adherence to guidelines | |
| Patient-related aspects |
|
| Drug industry-related aspects | |
| Health economic aspects |
Categories and quotations for the theme “GP-related influencing factors”
|
|
|
|---|---|
|
| “… and then I feel free, that if it doesn’t work with these basic drugs, it’s not a problem to prescribe something else …” |
| “… it is easy to check with the list … and maybe I don’t have the same critical judgement as before, but on the other hand I save time, because I perhaps wouldn’t have had the time anyway …” | |
|
| “It has a lot to do with our stress, that we don’t have the time to sit and read |
| “A good thing to bring up, I think, is the new electronic medical records system, PMO, that [the prescriptions] are there, so it is very easy to prescribe a recommended drug, which is very positive”. | |
| “I didn’t even know that the guidelines were there, where do you find them?” | |
|
| “… then I wonder a little bit…they are after all human beings … these groups who sit and write the guideline, I mean … we don’t know how active and good the doctors in these groups are …” |
| “…then I wonder, why does it have to be local, does it have to be different … in every region … are the patients different?” | |
| “The background information? Yes, it is very robust and good. If I didn’t have that book I perhaps wouldn’t have been as … satisfied or had the same confidence, because I can … read about what they considered and how the drugs work”. | |
| “But it feels quite uncomfortable, because they’re new drugs that we’ve heard so many good things about, and they cost a lot, but you sit there and wonder … well … nobody else tries it …” | |
|
| “A barrier would also be, as I said, a lack of options. It is a barrier to following guidelines, because you don’t know whether it will work in the next step …” |
| “Sometimes they come with different pills from the hospital, which they don’t need, and then we are supposed to withdraw them and prescribe the recommended ones. I can say that often the patient goes along with it, because I have the book there with the guidelines …” | |
| “It is actually aimed at GPs; hospital doctors don’t read it.” “Sometimes it feels that they don’t know what we are doing … they are supposed to follow the guidelines for the drug … but I don’t think they do…” | |
| “Yes, I agree with you, C … if a patient has a drug that works I don’t change it either just because they change the guidelines. Because … I don’t want to make the poor old patients more confused than they already are…” |
aA Swedish-language medical periodical.
Categories and quotations for the theme “External influencing factors”
|
|
|
|---|---|
|
| “Yes, you should never experiment with patients … or expose them to risk of injury. It is very important. This is why I think that we GPs are very careful with new drugs. I prefer to wait a while with a new drug before I prescribe it …” |
| “You might think so, but the patient may think differently …” | |
| “ … I think it is very important not to give in, at least in those cases with tetracycline versus penicillin, it feels important to explain to the patient the risk of bacterial resistance and so on … so there you can compromise a bit on the patient-doctor relationship …” | |
|
| “A conflict arises sometimes. Some patients are so well-read and influenced by the media and sometimes want another drug and … insist …” |
| “We don’t know anything about that. We don’t know if somebody there is on Pfizer’s board … or is biased …” | |
| “… and then you think about how life was before the [local] guidelines even existed. … we were drug industry indoc … formed … (laughs)” | |
|
| “…I think that it is OK to save money on things you can save money on … maybe to be able to do more tests of that kind or something else … the budget is not unlimited, so I usually think that this is not a problem.” |
| “… but there is a lot of focus on economy here, more focus on economy than on the pharmacological benefit compared to other drugs … so from that point of view it is highly controlled …” | |
| “I am not really sure if the economy part motivates us …” | |
| “The goal is to save money, I suppose, and more and more of the drug costs are transferred to the primary health care centres … so of course it matters …” |